CN102149682B - 1-(取代芳基)-5-三氟甲基-2-(1h)吡啶酮化合物及其盐的制备方法及其用途 - Google Patents
1-(取代芳基)-5-三氟甲基-2-(1h)吡啶酮化合物及其盐的制备方法及其用途 Download PDFInfo
- Publication number
- CN102149682B CN102149682B CN2010800025583A CN201080002558A CN102149682B CN 102149682 B CN102149682 B CN 102149682B CN 2010800025583 A CN2010800025583 A CN 2010800025583A CN 201080002558 A CN201080002558 A CN 201080002558A CN 102149682 B CN102149682 B CN 102149682B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- flumethiazine
- chloro
- ketone
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 56
- -1 3-(4-N-METHYL PIPERAZINE-1-yl) propyl Chemical group 0.000 claims description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
- 125000003368 amide group Chemical group 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 5
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 229960005181 morphine Drugs 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 3
- 230000002300 anti-fibrosis Effects 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 abstract description 12
- 230000004761 fibrosis Effects 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 description 38
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 229960003073 pirfenidone Drugs 0.000 description 15
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 12
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 229910052801 chlorine Inorganic materials 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 238000004043 dyeing Methods 0.000 description 8
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000013375 chromatographic separation Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 239000000428 dust Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- JDZYVVUJIQYGRX-UHFFFAOYSA-N 1-(3-fluorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC(F)=C1 JDZYVVUJIQYGRX-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 5
- 235000015320 potassium carbonate Nutrition 0.000 description 5
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 230000003176 fibrotic effect Effects 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 235000015110 jellies Nutrition 0.000 description 4
- 239000008274 jelly Substances 0.000 description 4
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 235000007715 potassium iodide Nutrition 0.000 description 4
- 229960004839 potassium iodide Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229950005953 camsilate Drugs 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000749 insecticidal effect Effects 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 3
- 150000003222 pyridines Chemical class 0.000 description 3
- 150000005299 pyridinones Chemical class 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 201000002793 renal fibrosis Diseases 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 210000000626 ureter Anatomy 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 2
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000003328 fibroblastic effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 2
- 229960000658 sumatriptan succinate Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- ZTVZLYBCZNMWCF-PHDIDXHHSA-N (2r)-2-azaniumyl-4-[[(3r)-3-azaniumyl-3-carboxylatopropyl]disulfanyl]butanoate Chemical class OC(=O)[C@H](N)CCSSCC[C@@H](N)C(O)=O ZTVZLYBCZNMWCF-PHDIDXHHSA-N 0.000 description 1
- OREKERSNHHDONJ-HSZRJFAPSA-N (2r)-n-[4-(benzimidazol-1-yl)-2-fluorophenyl]-2-(5-carbamimidoyl-1h-indol-3-yl)-3-phenylpropanamide Chemical compound C([C@H](C1=CNC2=CC=C(C=C21)C(=N)N)C(=O)NC=1C(=CC(=CC=1)N1C2=CC=CC=C2N=C1)F)C1=CC=CC=C1 OREKERSNHHDONJ-HSZRJFAPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UWTATZPHSA-N (R)-malic acid Chemical compound OC(=O)[C@H](O)CC(O)=O BJEPYKJPYRNKOW-UWTATZPHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical class OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 1
- HUTXVUPGARJNHM-UHFFFAOYSA-N 1-(2-chloroethoxy)ethanol Chemical compound CC(O)OCCCl HUTXVUPGARJNHM-UHFFFAOYSA-N 0.000 description 1
- AUERUDPETOKUPT-UHFFFAOYSA-N 1-(3-chloropropyl)-4-methylpiperazine Chemical compound CN1CCN(CCCCl)CC1 AUERUDPETOKUPT-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- HYOAGWAIGJXNQH-UHFFFAOYSA-N 1-bromo-1-chloropropane Chemical compound CCC(Cl)Br HYOAGWAIGJXNQH-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- PWJNDVAKQLOWRZ-UHFFFAOYSA-N 1-hydroxynaphthalene-2-sulfonic acid Chemical compound C1=CC=C2C(O)=C(S(O)(=O)=O)C=CC2=C1 PWJNDVAKQLOWRZ-UHFFFAOYSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- DPHCXXYPSYMICK-UHFFFAOYSA-N 2-chloro-1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C(Cl)=C1 DPHCXXYPSYMICK-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-M 3-(N-morpholino)propanesulfonate Chemical compound [O-]S(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-M 0.000 description 1
- BYRJSCNPUHYZQE-UHFFFAOYSA-N 5-(trifluoromethyl)-1h-pyridin-2-one Chemical compound OC1=CC=C(C(F)(F)F)C=N1 BYRJSCNPUHYZQE-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N 5-oxo-D-proline Chemical compound OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- YCPXWRQRBFJBPZ-UHFFFAOYSA-N 5-sulfosalicylic acid Chemical compound OC(=O)C1=CC(S(O)(=O)=O)=CC=C1O YCPXWRQRBFJBPZ-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 1
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical class SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 150000008558 D-cysteines Chemical class 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical class OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical class C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical compound OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 241001062009 Indigofera Species 0.000 description 1
- ZTVZLYBCZNMWCF-WDSKDSINSA-N L,L-homocystine zwitterion Chemical class OC(=O)[C@@H](N)CCSSCC[C@H](N)C(O)=O ZTVZLYBCZNMWCF-WDSKDSINSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 150000008538 L-cysteines Chemical class 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical class [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical class C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- SKBGMHDSWYMBIO-UHFFFAOYSA-N OCCNc(cc1)cc(Cl)c1N(C=C(C(F)(F)F)C=C1)C1=O Chemical compound OCCNc(cc1)cc(Cl)c1N(C=C(C(F)(F)F)C=C1)C1=O SKBGMHDSWYMBIO-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000031816 Pathologic Dilatation Diseases 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Natural products P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 102000049939 Smad3 Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- JIMXXGFJRDUSRO-UHFFFAOYSA-N adamantane-1-carboxylic acid Chemical class C1C(C2)CC3CC2CC1(C(=O)O)C3 JIMXXGFJRDUSRO-UHFFFAOYSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000002521 alkyl halide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- LEVWYRKDKASIDU-UHFFFAOYSA-N cystine Chemical class OC(=O)C(N)CSSCC(N)C(O)=O LEVWYRKDKASIDU-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- SEGLCEQVOFDUPX-UHFFFAOYSA-N di-(2-ethylhexyl)phosphoric acid Chemical compound CCCCC(CC)COP(O)(=O)OCC(CC)CCCC SEGLCEQVOFDUPX-UHFFFAOYSA-N 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950007655 esilate Drugs 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- FCQJEPASRCXVCB-UHFFFAOYSA-L flavianate Chemical compound C1=C(S([O-])(=O)=O)C=C2C([O-])=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FCQJEPASRCXVCB-UHFFFAOYSA-L 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- ZTVZLYBCZNMWCF-UHFFFAOYSA-N homocystine Chemical class [O-]C(=O)C([NH3+])CCSSCCC([NH3+])C([O-])=O ZTVZLYBCZNMWCF-UHFFFAOYSA-N 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-N iron;hydrochloride Chemical compound Cl.[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 229940116298 l- malic acid Drugs 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical group FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 1
- 229950005216 napadisilate Drugs 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical compound PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 150000003147 proline derivatives Chemical class 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 208000037999 tubulointerstitial fibrosis Diseases 0.000 description 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
一种1-取代芳基-5-三氟甲基-2-(1H)吡啶酮类化合物及其药学上可用的盐,以及所述化合物及其盐的制备方法和它们在制备治疗纤维化药物中的用途。
Description
技术领域
本发明涉及1-取代芳基-5-三氟甲基-2-(1H)吡啶酮类化合物。本发明还涉及它们的制备方法以及医药用途。
背景技术
纤维化(fibrosis)可发生于多种器官或组织,引起器官或组织内实质细胞减少,纤维结缔组织增多,最终可导致器官或组织结构破坏和功能减退,甚至器官衰竭。目前对器官或组织纤维化的发生机制、诊断方法和防治措施已进行了广泛的研究,现有技术中,在某些方面已取得了长足的进步,但仍有一些关键问题没有解决。
美国专利US3839346A,US4052509A,US4042699公开了29个具有下列结构式I的吡啶酮类化合物。
并公开了此类吡啶酮具有抗炎、解热、降低血清尿酸水平、止痛等作用。其中,1-苯基-5-甲基-2-(1H)吡啶酮(5-methyl-1-phenyl-2(1H)-pyridone,Pirfenidone)具有最好的活性和较低的毒性。
美国专利US5,310,562在1994年第一次公布了1-苯基-5-甲基-2-(1H)吡啶酮,[5-methyl-1-phenyl-2(1H)-pyridone]又称吡非尼酮(Pirfenidone,PFD)具有抗纤维化的生物活性,随后美国专利US5,518,729和US5,716,632宣称N-取代-2(1H)-吡啶酮[N-substituted2-(1H)pyridone],即结构式I,和N-取代-3(1H)-吡啶酮[N-substituted3-(1H)pyridone]也具有吡非尼酮(Pirfenidone)一样的抗纤维化作用。并列举了44个化合物,其中的大部分都是引自美国专利US4052509的已知化合物,在这些化合物中,R1、R2、R3、R4都限定在甲基或乙基。
吡非尼酮,(pirfenidone,PFD),在抗纤维化方面的有效性得到了更多体外和动物实验的证实。实验表明,在肾纤维化、肺纤维化动物实验和特异性肺纤维化病人的临床治疗中,吡非尼酮均具有阻止甚至逆转ECM聚积的作用和防止甚至逆转纤维化发生和瘢痕形成(Shimizu T, Fukagawa M,Kuroda T, et al.Pirfenidone prevents collagen accumulation inthe remnant kidney in rats with partial nephrectomy.Kidney Int,1997,52(Suppl 63):S239-243;Raghu G, Johnson WC,Lockhart D,et al.Treatment of idiopathic pulmonaryfibrosis with a new antifibrotic agent,pirfenidone.Am J Respir Crit Care Med,1999,159:1061-1069)。
本申请人申请了中国专利ZL02114190.8,提供了一类吡啶酮化合物,具有如下的结构II。
当n=1时,所述的取代基R表示F、Br、I。
当n=2时,所述的取代基R表示F、Cl、Br、I,饱和直链烃基、氧代饱和直链烃基、卤代饱和直链烃基。
所述的取代基团R在苯环上的位置具有邻位、间位、对位等方式。
吡非尼酮已经于2008年在日本以治疗肺纤维化的适应症上市。但吡非尼酮及其衍生物作用强度不大。吡非尼酮临床的日剂量达到了2400mg。
WO2007053685、WO2006122154公开了一类具有p38激酶抑制作用的化合物,这些化合物可用于纤维化疾病的治疗。其结构见结构III:
其中:R1~4为H、烷基、取代烷基、烯基、卤烷基、硝基烷基、羟烷基、烷氧基、苯基、取代苯基、卤素、羟基、烷氧基烷基、羧基、烷氧基羰基等;Xl~5为H、卤素、烷氧基、羟基。
WO2007062167也公开了一些具有p38激酶抑制作用的化合物,这些化合物也可用于各种纤维化的治疗。其中的一些结构如下:
这些化合物的苯环上均为一些简单的取代基。
中国专利200710034357也公开了具有一些上述结构的类似化合物化合物具有抗纤维化活性,同时还公开了具有结构IV的化合物具有抗纤维化活性。
这些化合物在吡啶酮环的5位引入了三氟甲基,可以改善吡非尼酮作用弱的缺点。但这些化合物的作用强度仍然不高。
德国专利DE4343528报道了一类化合物在农业上具有杀虫作用,具有如下的结构式V。
结构V中A、B均为各类杂环如呋喃环、咪唑、吡啶、吡啶酮取代;其中包含了一类如结构式VI的化合物。
欧洲专利EP259048、EP367410、EP398499报道了一类化合物在农业上具有杀虫作用,具有如下的结构式VII。
其中包含了一类结构R1为吡啶酮,具有结构式VIII的化合物。
其中的R10为O或S。
欧洲专利EP216541报道了一类化合物在农业上具有杀虫作用,具有如下的结构式IX。
其中包含了一类结构式X的化合物:
欧洲专利EP488220报道了一类化合物具有除草剂作用,具有如下的结构式XI。
以上的这些化合物在结构中,无论是吡啶环还是吡啶环1位的苯环上均有多种、多个取代基,结构复杂,而且没有抗纤维化的报道。
DE102004027359公开了一类能够调节多巴胺3受体的化合物,这些化合物可用于帕金森氏症和精神分裂症的治疗。具有如下的结构式XII。
其中:A是:4~6个原子数的碳氢链,碳链上可以有1~2个甲基取代。碳链中也可以有1~2个碳原子被氧、羰基、硫等其他原子取代。
R1和R2是:H;CN;NO2;卤原子;OR5;NR6R7;C(O)NR6R7;O-C(O)NR6R7;C1-C6的烷基;C1-C6的卤烷基等。
由此可见,在已有的发明中,抗纤维化化合物活性仍然不高。且由于分子中引入了多个氟原子,化合物的脂溶性强。同时,由于分子中没有水溶性大的基团,不能做成溶液剂使用。
发明内容
本发明提供的1-取代苯基-5-三氟甲基-2-(1H)吡啶酮化合物具有式(XIII)的结构。
其中,R1~R4,R12选自:H,CN,NO2,羟基,氨基,卤原子,C1-C6的烷氧基,NR10R11,OR13,C(O)R14,O-C(O)R14R15,C1-C6的烷基,C1-C6的卤烷基,C2-C6的烯基,羧基,羧酸酯;其中,R14、R15为:C1-C6的烷基;R10和R11选自:H,C1-C6羟烷基,酯化的C1-C6羟烷基,C1-C6烷氧基烷基,或结构式XIV;
且R1~R4、R12至少一个为NR10R11或OR13,OR13为C1-C6羟烷基,C1-C6烷氧基烷基;R10和R11不同时为H;;
结构式XIV中,R5选自:H,C1-C6的烷基,C1-C6的卤烷基,C1-C6羟烷基,酯化的C1-C6羟烷基,C2-C6的烯基;R6~R9选自:H,C1-C6的烷氧基,=O,C1-C4的烷基,C1-C4的卤烷基,C1-C4羟烷基,C2-C4的烯基;X选自N,CH2;Y选自N,O,C;n为:1~6;
及其药学上可用的盐。
更优选R12是NR10R11或OR13。
根据本发明的实施例,本发明进一步优选当R12是NR10R11或OR13时,R1~R4中有一个是卤原子,其余为H。
根据本发明的实施例,本发明优选下列化合物:
1-(2-氯-4-((3-(4-甲基哌嗪-1-基)丙基)胺基)苯基)-5-三氟甲基吡啶-2(1H)-酮(化合物1)
1-(2-氯-4-((3-吗啉基丙基)胺基)苯基)-5-三氟甲基吡啶-2(1H)-酮(化合物2)
1-(2-氯4-((3-哌啶-1-基)丙基胺基)苯基)-5-三氟甲基吡啶-2(1H)-酮(化合物3)
1-(4-((3-丁氧丙基)胺基)-2-氯苯基)-5-三氟甲基吡啶-2(1H)-酮(化合物4)
1-(2-氯-4-((2-羟基乙基)氨基)苯基)-5-三氟甲基吡啶-2(1H)-酮(化合物5)
1-(4-(N,N-二(2-羟基乙基)氨基)-2-氯苯基)-5-三氟甲基吡啶-2(1H)-酮(化合物6)
1-(2-氯-4-(((3-哌啶-1-基)丙基)胺基)苯基)-5-三氟甲基吡啶-2(1H)-酮盐酸盐(化合物7)
1-(2-氯-4-((2-(2-羟基乙氧基)乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮的制备(化合物8)
1-((4-((哌嗪-1-基)乙基)氨基)-2-氯苯基)-5-三氟甲基吡啶-2(1H)-酮(化合物9)
1-(2-氯-4-((2-(哌啶基-1-基)乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮(化合物10)
1-(2-氯-4-((2-吗啡啉乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮(化合物11)
1-(2-氯-4-((2-(4-甲基哌嗪-1-基)乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮(化合物12)
1-(2-氯-4-((2-(4-(2- 羟基乙基)哌嗪-1-基)乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮(化合物13)
及其药学上可用的盐。
所说的盐可以是盐酸盐、硫酸盐、磷酸盐、高氯酸盐、甲磺酸盐、三氟甲磺酸盐、甲酸盐,乙酸盐、丙酸盐、丁酸盐、马来酸盐、丁二酸盐、三氟乙酸盐、琥珀酸盐、水杨酸盐、DL-天冬氨酸盐、D-天冬氨酸盐、L-天冬氨酸盐、DL-谷氨酸盐、D-谷氨酸盐、L-谷氨酸盐、甘油酸盐、琥珀酸盐、硬脂酸盐、DL-酒石酸盐、D-酒石酸盐、L-酒石酸盐、(±)扁桃酸盐、(R)-(-)扁桃酸盐、(S)-(+)-扁桃酸盐、柠檬酸盐、粘酸盐、马来酸盐、丙二酸盐、苯甲酸盐、DL-苹果酸盐、D-苹果酸盐、L-苹果酸盐、半苹果酸盐、l-金刚烷乙酸盐、1-金刚烷羧酸盐、黄安酸盐、磺基乙酸盐、(±)-乳酸盐、L-(+)-乳酸盐、D-(-)-乳酸盐、扑酸盐、D-α-半乳糖醛酸盐、甘油酸盐、DL-胱氨酸盐、D-胱氨酸盐、L-胱氨酸盐、DL-高胱氨酸盐、D-高胱氨酸盐、L-高胱氨酸盐、DL-半胱氨酸盐、D-半胱氨酸盐、L-半胱氨酸盐、(4S)-羟基-L-脯氨酸、环丙烷-1,1-二羧酸盐、2,2-甲基丙二酸盐、酪氨酸盐、脯氨酸盐、富马酸盐、1-羟基-2萘甲酸盐、膦酰基乙酸盐、碳酸盐、碳酸氢盐、3-膦酰基丙酸盐、DL-焦谷氨酸盐、D-焦谷氨酸盐和L-焦谷氨酸盐、甲苯磺酸盐、苯磺酸盐、乙磺酸盐、(±)樟脑磺酸盐、萘磺酸盐、1R-(-)-樟脑磺酸盐、1S-(+)-樟脑磺酸盐、1,5-萘二磺酸盐、1,2-乙烷二磺酸盐、1,3-丙烷二磺酸盐、3-(N-吗啉代)丙烷磺酸盐、联苯基磺酸盐、羟乙磺酸盐和1-羟基-2-萘磺酸盐、磷酸二氢盐、磷酸氢钾盐、磷酸二钾盐、磷酸钾盐、磷酸氢钠盐、磷酸二钠盐、磷酸钠盐、磷酸二氢钠盐、磷酸钙盐、三代磷酸钙盐和六氟代磷酸盐、乙烯基膦酸盐、2-羧基乙基膦酸盐和苯基膦酸盐。
本发明还提供式XIII化合物的合成方法,合成路线如下。对于简单氨基取代的化合物,使用5-三氟甲基-2(1H)吡啶酮与硝基取代氟苯反应,DMSO作溶剂,碳酸钾做缚酸剂,碘化钠做催化剂,制得硝基取代物,盐酸铁粉还原,制得氨基取代物,再根据不同化合物制得目标产物。见反应式I。
对于氨基通过脂肪侧链与杂环相连的化合物,首先使用溴氯丙烷与杂环化合物反应,得到氯烷基杂环化合物,再与按照反应式I制得的氨基取代物反应,得到目标产物,正丁醇做溶剂,碘化钠做催化剂,微波催化。见反应式II。
或者,按照反应式I制得羟乙基氨基取代物,与二氯亚砜反应制得氯乙基氨基取代物,再与杂环化合物反应制得目标产物。见反应式III。
合成起始物三氟甲基吡啶酮为商品化原料。
上述化合物可以用于制备一种广谱纤维化的药物。
本发明是在上述现有技术基础上,在吡啶酮1位的苯环上引入取代氨基,在该氨基上通过一个烷基链引入一个亲水性基团如羟基、杂环等,得到一类新的吡啶酮类化合物及其盐。这些化合物的活性也大大增加。
本申请人发现,在1-苯基-5-三氟甲基吡啶酮的基础上,对苯基再进行修饰,用取代基氨基修饰苯基,取得了意想不到的效果,所获得的化合物具有比现有吡啶酮化合物具有相对高的药效。同时,这类含杂环的化合物可以做成各种盐,有利于做成各种液体制剂。
本申请人通过实验发现,本发明提供的化合物,与现有技术中吡啶酮化合物一样具有好的抗纤维化的药理作用,但药效比现有技术中吡非尼酮明显强,最高可达60多倍。因此,本发明还提供式XIII所示的化合物在制备抗纤维化药物中的用途。
附图说明
图1实施例15中肾脏病理HE染色(×200);
图2实施例15中肾脏病理Masson染色(×200)。
具体实施方式
实施例1 1-(2-氯-4-((3-(4-甲基哌嗪-1-基)丙基)胺基)苯基)-5-三氟甲基吡啶-2(1H)-酮的制备
(化合物1)
A、1-(2-氯-4-硝基苯基)-5-三氟甲基吡啶-2(1H)-酮的制备
8.2g(0.050mol)5-三氟甲基吡啶-2(1H)-酮,加DMSO100mL溶解,投入13.1g(0.075mol)3-氯-4-氟硝基苯,11.0g(0.080mol)碳酸钾,1.4g碘化钠,130℃下搅拌反应4小时,反应完毕冷却至40℃,加入100mL12%氨水,析出大量沉淀,过滤,滤渣乙酸乙酯溶解,活性炭脱色,过滤,滤液无水硫酸钠干燥,滤除硫酸钠,回收溶剂,过滤得产物1-(2-氯-4-硝基苯基)-5-三氟甲基吡啶-2(1H)-酮。棕黄色固体12.0g。m.p.:217.7~218.3℃。MS(m/z):318(M+)。1H-NMR(CDCl3,300MHz)δ ppm:6.769~6.800(d,1H,Ar-H,J=3.3Hz),7.579~7.570(t,3H,Ar-H),8.296~8.333(dd,1H,J=3.3Hz,8.7Hz,Ar-H),8.492(s,1H,Ar-H)。
B、1-(4-氨基-2-氯苯基)-5-三氟甲基吡啶-2(1H)-酮的制备
12.0g(0.035mol)1-(2-氯-4-硝基苯基)-5-三氟甲基吡啶-2(1H)-酮,200mL50%乙醇,5.8g(0.105mol)还原铁粉,加热至回流,缓慢滴加0.42mL(0.004mol)浓HCl(用5mL50%乙醇稀释后滴加),搅拌回流反应5小时,反应完毕,15%KOH乙醇溶液调pH至10,过滤,滤渣用95%乙醇洗涤(2*10mL),滤液蒸干乙醇后用乙酸乙酯萃取(50mL*3),有机相用无水硫酸钠干燥过夜,过滤,滤液蒸干得产物1-(4-氨基-2-氯苯基)-5-三氟甲基吡啶-2(1H)-酮,土黄色粉末状固体10.2g。m.p.:136~138℃。EI-MS(m/z):288[M]+。1H-NMR(CDCl3,300MHz)δ ppm:3.559(br,2H,-NH2),6.633~6.670(dd,1H,J=2.7 Hz,8.7HzAr-H),6.708~6.740(d,1H,J=9.6Hz,Ar-H),6.820~6.828(d,1H,2.4Hz,Ar-H),7.089~7.1 17(d,1H,J=2.4Hz,Ar-H),7.503~7.544(dd,1H,2.7Hz,9.6Hz,Ar-H),7.595(s,1H,Ar-H)。
C、1-(3-氯丙基)-4-甲基哌嗪的制备
0.1mol哌啶,100mL丙酮,0.125mol氢氧化钠(25%),冰浴控温在5°以下,缓慢滴加0.1mol1-氯-3-溴丙烷,滴加完毕,室温25℃反应48小时,反应完毕,减压蒸干溶剂,加入50mL水溶解,用二氯甲烷萃取(3*50mL),合并有机相,硫酸钠干燥过夜,过滤,减压蒸干后得油状物,滴加浓盐酸至pH=1~2,加二氯甲烷打浆除1-氯-3-溴丙烷,滤渣加水适量溶解,用25%氢氧化钠调pH=12,用二氯甲烷萃取(20mL*3),硫酸钠干燥,过滤减压蒸干得黄色油状物1.0g,收率14.2%。1H-NMR(CDCl3,300MHz)δ:1.930~1.999(m,2H,-CH2-),2.301(s,3H,-CH3),2.470~2.517(m,10H,-CH2-),3.575~3.619(t,2H,-CH2-)。
D、1-(2-氯-4-((3-(4-甲基哌嗪-1-基)丙基)胺基)苯基)-5-三氟甲基吡啶-2(1H)-酮的制备
2.59g(0.003mol)1-(4-氨基-2-氯苯基)-5-三氟甲基吡啶-2(1H)-酮加15mL正丁醇溶解,再加入0.528g(0.001mol)1-(3-氯)丙基-4-甲基哌嗪搅拌混匀,催化量碘化钾,170℃微波反应。反应完毕,过滤,滤液蒸去溶剂,残渣柱层析分离,石油醚∶乙酸乙酯=1∶1(1%三乙胺)洗脱,得0.15g黄色固体。m.p.:129~132℃。ESI-MS(m/z):429[M+H]+。1H-NMR(CDCl3,300MHz)δ ppm:1.805~1.845(m,2H,-CH2-),2.369(s,3H,-CH3),2.534~2.575(t,10H,-CH2-),3.201(br,2H,-CH2-),5.501(br,1H,-NH-),6.5 16~6.553(dd,1H,J=2.4Hz,8.7Hz,Ar-H),6.678~6.734(dd,1H,J=2.4Hz,7.2Hz,Ar-H),7.071~7.100(d,1H,J=8.7Hz,Ar-H),7.491~7.532(dd,1H,J=2.7Hz,9.6Hz,Ar-H),7.604(s,1H,Ar-H)。
实施例2 1-(2-氯-4-((3-吗啉基丙基)胺基)苯基)-5-三氟甲基吡啶-2(1H)-酮的制备
(化合物2)
0.54g(0.003mol)1-(4-氨基-2-氯苯基)-5-三氟甲基吡啶-2(1H)-酮加5mL正丁醇溶解,再加入0.528g(0.001mol)1-(3-氯)丙基-吗啉和催化量碘化钾搅拌混匀,180℃微波反应。反应完毕,过滤,滤液蒸干,残渣层析分离,石油醚∶乙酸乙酯=1∶1(1%三乙胺)洗脱,得0.16g黄色固体。m.p.:95~97℃。ESI-MS(m/z):416[M+H]+。1H-NMR(CDCl3,300MHz)δ ppm:1.836~1.856(m,2H,-CH2-),2.527(br,6H,-CH2-),3.202~3.258(t,2H,-CH2-),3.777(br,4H,-CH2-),5.403(br,1H,-NH-),6.523~6.559(dd,1H,J=2.4Hz,8.7Hz,Ar-H),6.689~6.698(d,1H,J=2.7Hz,Ar-H),6.737(s,1H,Ar-H),7.078~7.138d,1H,J=8.7Hz,Ar-H),7.493~7.534(dd,1H,J=2.7Hz,9.9Hz,Ar-H),7.604(s,1H,Ar-H)。
实施例3 1-(2-氯4-((3-哌啶-1-基)丙基胺基)苯基)-5-三氟甲基吡啶-2(1H)-酮的制备
(化合物3)
3.50g(0.012mol)1-(4-氨基-2-氯苯基)-5-三氟甲基吡啶-2(1H)-酮加15mL正丁醇溶解,再加入0.528g(0.004mol)1-(3-氯)丙基哌啶搅拌混匀,催化量碘化钾,180℃微波反应。反应完毕,过滤,滤液蒸干,残渣柱层析分离,石油醚∶乙酸乙酯=1∶1(1%三乙胺)洗脱,得0.21g浅咖啡色固体。m.p.:112~115℃。EI-MS(m/z):413[M]+。1H-NMR(CDCl3,300MHz)δ ppm:1.482~1.489(m,2H),1.607~1.642(m.4H),1.736~1.843(m,2H),2.425~2.491(m,6H),3.185(br,2H),6.011(br,1H-NH-),6.499~6.537(dd,1H,J=2.7Hz,8.7Hz,Ar-H),6.654~6.662(d,1H,J=2.4Hz,Ar-H),6.698~7.73 1(d,1H,J=9.9Hz,Ar-H),7.059~7.088(d,1H,J=8.7Hz,Ar-H),7.483~7.524(dd,1H,J=2.7Hz,9.9Hz,Ar-H),7.607(s,1H,Ar-H)。
实施例4 1-(4-((3-丁氧丙基)胺基)-2-氯苯基)-5-三氟甲基吡啶-2(1H)-酮的制备
(化合物4)
2.88g(0.01mol)1-(4-氨基-2-氯苯基)-5-三氟甲基吡啶-2(1H)-酮加15mL正丁醇溶解,再加入3.14g(0.02mol)1-氯-3-溴丙烷搅拌混匀,催化量碘化钾,180℃微波反应。反应完毕,过滤,滤液蒸干,残渣柱层析分离,石油醚∶乙酸乙酯=3∶1(1%三乙胺)洗脱,得0.20g类白色固体。m.p.:83.0~85.0℃。ESI-MS(m/z):425[M+Na]+。1H-NMR(CDCl3,300MHz)δ ppm:0.921~0.970(t,3H,-CH3),1.364~1.439(m,2H,-CH2-),1.563~1.612(m,2H,-CH2-),1.880~1.919(m,2H,-CH2-),3.213~3.255(t,H,-CH2-),3.415~3.458(t,2H,-CH2-),3.542~3.579(t,2H,-CH2-),4.696(br,1H,-NH-),6.508~6.545(dd,1H,J=2.4 Hz,2.4Hz,Ar-H),6.680~6.689(d,1H,J=2.7Hz,Ar-H),.704~6.736(d,1H,J=9.6Hz,Ar-H),7.070~7.099(d,1H,J=8.7Hz,Ar-H),7.491~7.532(dd,1H,J=2.7Hz,2.4Hz,Ar-H),7.606(s,1H,Ar-H)。
实施例5 1-(2-氯-4-((2-羟基乙基)氨基)苯基)-5-三氟甲基吡啶-2(1H)-酮的制备
(化合物5)
0.57g(0.002mol)1-(4-氨基-2-氯苯基)-5-三氟甲基吡啶-2(1H)-酮,12mL氯乙醇和12mLDMF溶解,再加入0.56g(0.004mol)碳酸钾,130℃下搅拌反应12小时,反应完毕,过滤,滤液蒸干,残渣柱层析分离,石油醚∶乙酸乙酯=1∶1洗脱,得棕褐色固体0.080g。m.p.:161.0~164.0℃。EI-MS(m/z):332[M]+。1H-NMR(CDCl3,300MHz)δ ppm:3.504~3.543(t,2H,-CH2-),3.658~3.709(t,2H-CH2-),4.412(br,1H,-NH-),6.590~6.627(dd,1H,J=2.7Hz,2.4Hz,Ar-H),710~6.742(d,1H,J=9.6Hz,Ar-H),6.754~6.762(d,1H,J=2.4Hz,Ar-H),7.128~7.157(d,1H,J=8.7Hz,Ar-H),7.500~7.542(dd,1H,J=2.7Hz,9.6Hz,Ar-H),7.597(s,1H,Ar-H)。
实施例6 1-(4-(N,N-二(2-羟基乙基)氨基)-2-氯苯基)-5-三氟甲基吡啶-2(1H)-酮的制备
(化合物6)
0.57g(0.002mol)1-(4-氨基-2-氯苯基)-5-三氟甲基吡啶-2(1H)-酮,12mL氯乙醇和12mLDMF溶解,再加入0.56g(0.004mol)碳酸钾,130℃下搅拌反应12小时,反应完毕,过滤,滤液蒸干,残渣柱层析分离,石油醚∶乙酸乙酯=1∶1洗脱,得棕红色固体0.070g。m.p.:169.0~172.0℃。EI-MS(m/z):376[M]+。1H-NMR(CDCl3,300MHz)δ ppm:3.213~3.245(t,4H,-CH2-),3.661~3,754(t,4H-CH2-),6.714~6.746(d,1H,J=9.6Hz,Ar-H),6.864~6.903(dd,1H,J=2.7 Hz,9.6Hz,Ar-H),7.018~7.027(d,1H,J=2.7Hz,Ar-H),7.214~7.244(d,1H,J=9.0Hz,Ar-H),7.505~7.514(dd,1H,J=2.7Hz,Ar-H)。
实施例71-(2-氯-4-(((3-哌啶-1-基)丙基)胺基)苯基)-5-三氟甲基吡啶-2(1H)-酮盐酸盐的制备
(化合物7)
2.9mmol的1-(4-(((3-哌啶-1-基)丙基)胺基)-2-氯苯基)-5-三氟甲基吡啶-2(1H)-酮,用乙醇适量溶解,加入2.mmol的盐酸搅拌反应2小时,蒸干溶剂得1-(2-氯4-(((3-哌啶-1-基)丙基)胺基)苯基)-5-三氟甲基吡啶-2(1H)-酮盐酸盐,类白色固体0.12g,M.P:192~195℃。EI-MS(m/z):414[M+H]+。1H-NMR(D2O)δ ppm:1.343~1.718(m,6H,-CH2-),1.857~1.905(2H,-H),1.956~2.055(m,2H,-CH2-),2.829~2.905(t,2H,-CH2-),3.122~3.116(t,2H,-CH2-),3.221~3.284(2H-CH2-),3.445~3.487(2H-CH2-),6.764~6.812(2H,Ar-H),6.965~6.972(1H,Ar-H),7.199~7.228(1H,Ar-H),7.785~7.907(1H,Ar-H),8.075(1H,Ar-H)。
实施例8 1-(2-氯-4-((2-(2-羟基乙氧基)乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮的制备
(化合物8)
1.9mmol的1-(4氨基-2-氯)苯基-5-三氟甲基吡啶-2(1H)-酮,28mmol氯乙氧基乙醇和50mL正丁醇溶解,再加入1.9mmol碳酸钾,回流反应72小时,过滤,滤液制沙柱层析分离,石油醚∶乙酸乙酯=1∶1洗脱,得黄色油状物0.33g。EI-MS(m/z):376[M]+,1H-NMR(CDCl3,300MHz)δ ppm:3.320~3.355(t,2H,-CH2-),3.607~3,637(t,2H,-CH2-),3.714~6.748((t,2H,-CH2-),3.768~3.798((t,2H,-CH2-),6.609~6.646(dd,1H,J=2.4Hz,8.4Hz,Ar-H),6.710-6.742(d,1H,J=9.6Hz,Ar-H),6.775~6.783(d,1H,J=2.4Hz,Ar-H),7.107~7.136(d,1H,J=8.7Hz,Ar-H),7.501~7.542(dd,1H,J=2.7Hz,9.6Hz,Ar-H),7.603(s,1H,Ar-H)。
实施例91-((4-((哌嗪-1-基)乙基)氨基)-2-氯苯基)-5-三氟甲基吡啶-2(1H)-酮的制备
(化合物9)
A 1-(2-氯-4-((2-氯乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮的制备
3mmol的1-(2-氯-4-((2-羟基乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮和120mL的二氯甲烷,4.5mmol的二氯亚砜和4.5mmol的三乙胺室温搅拌反应28小时,柱层析分离,石油醚∶乙酸乙酯=3∶1洗脱,得淡黄色固体0.5g,M.P:160.0~162.0℃。EI-MS(m/z):350[M]+。1H-NMR(CDCl3,300MHz)δ ppm:3.502~3.541(t,2H,-CH2-),3.713~3.752(t,2H,-CH2-),6.909~6.647(dd,1H,J=2.7Hz,8.7Hz,Ar-H),6.716~6.777(2H,Ar-H),7.135~7.164(d,1H,J=8.7Hz,Ar-H),7.508~7.550(dd,1H,J=2.7Hz,9.6Hz,Ar-H),7.600(s,1H,Ar-H)。B 1-(2-氯-4-((2-哌嗪-1-基)乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮的制备
1.3mmol的1-(2-氯-4-((2-氯乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮,7.8mmol无水哌嗪和50mL乙腈溶解,再加碘化钠适量,回流反应12小时,过滤,滤液制沙柱层析分离,乙酸乙酯∶甲醇=5∶1(2%三乙胺)洗脱,得黄色胶状物0.32g。EI-MS(m/z):400[M]+,1H-NMR(CDCl3,300MHz)δ ppm:2.442(s,4H,-CH2-),2.628(s,2H,-CH2-),2.904(s,4H,-CH2-),3.144~3.158(d,2H,-CH2-),4.776(s,1H,-NH-),6.572~6.60(d,1H,J=8.4Hz,Ar-H),6.707~6.736(d,1H,J=8.7Hz,Ar-H),7.094~7.122(d,1H,J=8.4Hz,Ar-H),7.500~7.530(d,1H,J=9.0Hz,Ar-H),7.609(s,1H,Ar-H)。
实施例10 1-(2-氯-4-((2-(哌啶基-1-基)乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮的制备
(化合物10)
1.7mmol的1-(2-氯-4-((2-氯乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮和10.3mmol哌啶,50m L乙腈溶解,再加碘化钠适量,回流反应17小时,过滤,滤液制沙柱层析分离,石油醚∶乙酸乙酯=1∶1洗脱,得黄色胶状物0.34g。EI-MS(m/z):399[M]+,1H-NMR(CDCl3,300MHz)δ ppm:1.470~1.487(d,2H,J=5.1,-CH2-),1.576~1.647(m,4H,-CH2-),2.436(s,4H,-CH2-),2.604~2.644(t,2H,-CH2-),3.152~3.165(d,2H,-CH2-),4.941(s,1H,-NH-),6.568~6.605(dd,1H,J=2.4Hz,8.7Hz,Ar-H),6.708~6.734(t,1H,Ar-H),7.088~7.1 17(d,1H,J=8.7Hz,Ar-H),7.493~7.502(d,1H,J=2.7Hz,Ar-H),7.525~7.534(d,-H,J=2.7Hz,Ar-H)。
实施例11 1-(2-氯-4-((2-吗啡啉乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮的制备
(化合物11)
1.7mmol的1-(2-氯-4-((2-氯乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮和10.9mmol吗啡啉,50mL乙腈溶解,再加碘化钠适量,回流反应24小时,过滤,滤液制沙柱层析分离,石油醚∶乙酸乙酯=1∶1洗脱,得黄色胶状物0.67g。EI-MS(m/z):401[M]+,1H-NMR(CDCl3,300MHz)δppm:2.500(s,4H,-CH2-),2.650~2.688(t,2H,-CH2-),3.150~3.204(m,2H,-CH2-),3.728~3.758(t,4H,-CH2-),4.781(s,1H),6.573~6.610(dd,1H,J=2.4Hz,6.0Hz,Ar-H),6.703~6.743(t,2H,Ar-H),7.098~7.127(d,1H,J=8.7Hz,Ar-H),7.494~7.535(dd,1H,J=2.7Hz,9.6Hz,Ar-H),7.603(s,1H,Ar-H)。
实施例12 1-(2-氯-4-((2-(4-甲基哌嗪-1-基)乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮的制备
(化合物12)
1.7mmol的1-(2-氯-4-((2-氯乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮和10.9mmol的N-甲基哌嗪,50mL乙腈溶解,再加碘化钠适量,回流反应22小时,过滤,滤液制沙柱层析分离,石油醚∶乙酸乙酯=1∶1洗脱,得黄色固体0.70g。m.p.:113.1~115.2,EI-MS(m/z):414[M]+,1H-NMR(CDCl3,300MHz)δ ppm:2.321(s,3H,-CH3),2.511(br,8H,-CH2-),2.639~2.678(t,2H,-CH2-),3.126~3.181(q,2H,-CH2-),4.736~4.765(t,1H,-NH-),6.566~6.603(dd,1H,J=2.4Hz,8.7Hz,Ar-H),6.708~6.740(t,2H,Ar-H),7.096~7.125(d,1H,J=9.6Hz,Ar-H),7.496~7.537(dd,1H,J=2.7Hz,9.6Hz,Ar-H),7.609(s,1H,Ar-H)。
实施例13 1-(2-氯-4-((2-(4-(2-羟基乙基)哌嗪-1-基)乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮的制备
(化合物13)
1.7mmpl的1-(2-氯-4-((2-氯乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮和10.9mmol的羟乙基哌嗪,50mL乙腈溶解,再加碘化钠适量,回流反应24小时,过滤,滤液制沙柱层析分离,石油醚∶乙酸乙酯=1∶1洗脱,得黄色胶状物0.51g。EI-MS(m/z):444[M]+。1H-NMR(CDCl3,300MHz)δppm:2.567~2.691(m,12H,-CH2-),3.139~3,192(t,2H,-CH2-),3.632~3.667(t,2H,-CH2-),4.737(br,1H,-NH-),6.563~6.600(dd,1H,J=2.4Hz,8.7Hz,Ar-H),6.702~6.738(t,2H,Ar-H),7.094~7.123(d,1H,J=8.7Hz,Ar-H),7.492~7.533(dd,1H,J=2.7Hz,9.0Hz,Ar-H),7.603(s,1H,Ar-H)。
实施例14 化合物对NIH3T3成纤维细胞的抑制试验
用噻唑蓝(MTT)方法。细胞用含5%小牛血清的DMEM培养基培养,将细胞制成3×104/ml的细胞悬液,每孔100μl接种于96孔板中。待细胞贴壁后换含不同浓度化合物和氟非尼酮的含1%小牛血清的培养基,每个浓度设3个复孔。分别于加药后48、72小时后,每孔加MTT溶液(培养基配成5mg/ml,过滤后避光保存)100μl,4小时后将MTT吸出,每孔加MTT溶解液DMSO150μl,10min后待MTT完全溶解,酶标仪测OD值。根据抑制率,计算氟非尼酮和测定化合物的IC50值。以两者的IC50值求得测定化合物的活性与氟非尼酮活性的倍数。再根据倍数和某一块板上氟非尼酮的IC50值求得测定化合物的相对IC50值。
被测化合物对NIH3T3成纤维细胞的抑制活性
注:倍数是指化合物IC50值与氟非尼酮IC50值
实施例15
观察化合物13对大鼠单侧输尿管梗阻肾纤维化模型的治疗效果。
一、 材料与方法
1、实验药品
化合物13按本发明提供的方法制备。
2、实验动物
雄性SD大鼠9只,体重188-213g,购自湖南斯莱克实验动物有限责任公司。实验动物每天予以12小时光照,饲料购自上海斯莱克实验动物有限责任公司,饮用水由中南大学实验动物学部提供。
3、实验方法
(1)随机分组:9只大鼠随机分为3组,分别为:正常组(n=3)、模型组(n=3)、化合物1315mg/kg治疗组(n=3),3只老鼠归为一笼。实验动物适应性喂养2天。
(2)单侧输尿管梗阻造模术:
每只大鼠按0.35ml/100g的10%水合氯醛腹腔注射麻醉,随后固定在大鼠固定板上。先用水浸润背部皮肤,然后将皮肤绷紧,用弯头手术剪紧贴皮肤去毛,常规消毒铺巾。
取左肋缘下1.0cm与脊柱正中线旁开0.8cm交界处做一纵向长1.0cm的切口,逐层分离,暴露左肾和左侧输尿管,紧贴左肾下极用4.0丝线结扎左侧输尿管,在其下方1cm处再结扎一处,在两结扎点之间离断输尿管,用庆大霉素生理盐水溶液冲洗腹腔,检查无渗漏和出血后逐层缝合后腹膜腔各层及背部皮肤。
(3)药物干预:造模手术前一天开始灌胃,每日一次,共12天。具体方法如下:
a)用CMCNa粉剂加入适当0.9%的生理盐水,配制成浓度为0.5%的CMCNa溶液,以下各组药物均以0.5%的CMCNa溶液作为溶剂配制。
b)正常组组:0.5%CMC-NA 6ml/kg.d灌胃,每天一次。
c)模型组:0.5%CMC-NA 6ml/kg.d灌胃,每天一次。
d)化合物1315mg/kg治疗组:6ml/kg.d灌胃,每天一次。
(4)动物处死及标本采集:
各组大鼠分别于术后第11天腹腔内注射10%水合氯醛(0.7-0.9ml/100g)麻醉过量处死,取得的梗阻侧肾组织用4%甲醛固定、石蜡包埋、制成4 μ m厚切片,行HE染色和Masson染色。
(5)HE染色评分标准
取肾组织HE染色切片,低倍镜下单盲依序观察左上、右上、左下、右下、中间5个肾小管间质视野,按肾间质损伤8项指标评分:肾小管上皮细胞空泡变性、肾小管扩张、肾小管萎缩、红细胞管型、蛋白管型、间质水肿、间质纤维化、间质炎性细胞浸润,计算其均值,作为该标本的肾小管间质损伤指数。评分标准参考文献:Radford MG Jr,Donadio JV Jr,Bergstralh EJ,et al.Predicting renal outcome in IgA nephropathy.J Am SocNephrol,1 997,8(2):199-207。
(6)Masson染色评分标准
取肾组织Masson染色切片,在400倍光学显微镜下,每个标本随机观察20个视野,计算呈蓝染的胶原所占视野的百分比,进行半定量评分后取均值:无阳性染色,0分;<25%,1分;25-50%,2分;50-75%,3分;>75%,4分。评分标准参考文献:Lin SL,Chen RH,Chen YM,et al.Pentoxifylline Attenuates Tubulointerstitial Fibrosis by Blocking Smad3/4-ActivatedTranscription and Profibrogenic Effects of Connective Tissue Growth Factor.J Am SocNephrol.2005,16:2702-2713。
4、统计方法采用单因素方差分析方法
二、实验结果
1、HE染色肾间质损伤病理评分结果
表1各组大鼠梗阻肾脏肾小管间质损伤指数的比较
注:
与正常组比较,☆p<0.05,☆☆p<0.01;☆☆☆p<0.001;
与模型组比较,*p<0.05,**p<0.01,***p<0.001;
2 MASSON染色肾间质损伤病理评分结果
表2各组大鼠左侧肾脏Masson染色肾间质胶原评分结果
注:
与正常组比较,☆p<0.05,☆☆p<0.01;☆☆☆p<0.001;
与模型组比较,*p<0.05,**p<0.01,***p<0.001;
三、结论
化合物13 15mg/kg能够有效治疗肾脏纤维化。
Claims (3)
2.1-取代苯基-5-三氟甲基-2-(1H)吡啶酮化合物,其特征在于所说的化合物为:
1-(2-氯-4-((3-(4-甲基哌嗪-1-基)丙基)胺基)苯基)-5-三氟甲基吡啶-2(1H)-酮;
1-(2-氯-4-((3-吗啉基丙基)胺基)苯基)-5-三氟甲基吡啶-2(1H)-酮;
1-(2-氯-4-((3-哌啶-1-基)丙基胺基)苯基)-5-三氟甲基吡啶-2(1H)-酮;
1-(4-((3-丁氧丙基)胺基)-2-氯苯基)-5-三氟甲基吡啶-2(1H)-酮;
1-(2-氯-4-((2-羟基乙基)氨基)苯基)-5-三氟甲基吡啶-2(1H)-酮;
1-(4-(N,N-二(2-羟基乙基)氨基)-2-氯苯基)-5-三氟甲基吡啶-2(1H)-酮;
1-(2-氯-4-(((3-哌啶-1-基)丙基)胺基)苯基)-5-三氟甲基吡啶-2(1H)-酮盐酸盐;
1-(2-氯-4-((2-(2-羟基乙氧基)乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮;
1-((4-((哌嗪-1-基)乙基)氨基)-2-氯苯基)-5-三氟甲基吡啶-2(1H)-酮;
1-(2-氯-4-((2-(哌啶基-1-基)乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮;
1-(2-氯-4-((2-吗啡啉乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮;
1-(2-氯-4-((2-(4-甲基哌嗪-1-基)乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮;
1-(2-氯-4-((2-(4-(2-羟基乙基)哌嗪-1-基)乙基)氨基)-苯基)-5-三氟甲基吡啶-2(1H)-酮。
3.抗纤维化药物,其特征在于含有权利要求1—2之一所述的化合物与药学上可接受的辅料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010800025583A CN102149682B (zh) | 2009-05-25 | 2010-05-24 | 1-(取代芳基)-5-三氟甲基-2-(1h)吡啶酮化合物及其盐的制备方法及其用途 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910043501 | 2009-05-25 | ||
CN200910043501.7 | 2009-05-25 | ||
PCT/CN2010/073105 WO2010135972A1 (zh) | 2009-05-25 | 2010-05-24 | 1-(取代芳基)-5-三氟甲基-2-(1h)吡啶酮化合物及其盐的制备方法及其用途 |
CN2010800025583A CN102149682B (zh) | 2009-05-25 | 2010-05-24 | 1-(取代芳基)-5-三氟甲基-2-(1h)吡啶酮化合物及其盐的制备方法及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102149682A CN102149682A (zh) | 2011-08-10 |
CN102149682B true CN102149682B (zh) | 2012-12-05 |
Family
ID=43222160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010800025583A Active CN102149682B (zh) | 2009-05-25 | 2010-05-24 | 1-(取代芳基)-5-三氟甲基-2-(1h)吡啶酮化合物及其盐的制备方法及其用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US8426407B2 (zh) |
EP (1) | EP2436670B1 (zh) |
JP (1) | JP5583758B2 (zh) |
KR (1) | KR101522924B1 (zh) |
CN (1) | CN102149682B (zh) |
AU (1) | AU2010252447B2 (zh) |
HK (1) | HK1164297A1 (zh) |
WO (1) | WO2010135972A1 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2691379C (en) | 2007-06-20 | 2015-06-09 | Auspex Pharmaceuticals, Inc. | Substituted n-aryl pyridinones |
KR102057877B1 (ko) * | 2012-07-18 | 2019-12-20 | 노스 앤드 사우스 브라더 파마시 인베스트먼트 컴파니 리미티드 | 질소함유 헤테로고리 유도체 및 그의 약물에서의 용도 |
CN102786467A (zh) * | 2012-08-15 | 2012-11-21 | 浙江省医学科学院 | 一种n-取代芳基吡啶酮化合物及其制备方法和应用 |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
EP3083584B1 (en) | 2013-12-19 | 2018-02-21 | Sunshine Lake Pharma Co., Ltd. | Nitrogenous heterocyclic derivatives and their application in the treatment of tissue fibrosis |
CA2943363A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
WO2015171345A1 (en) * | 2014-04-30 | 2015-11-12 | Auspex Pharmaceuticals, Inc. | N-aryl pyridinones modulators of fibrosis and/or collagen infiltration |
CN106466318B (zh) * | 2015-08-21 | 2019-01-01 | 中南大学 | 1-杂环取代苄基吡啶酮类化合物在制备治疗糖尿病肾病药物中的应用 |
CN113476447A (zh) * | 2021-07-09 | 2021-10-08 | 中南大学 | 一种美氟尼酮在制备急性肝损伤药物中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1386737A (zh) * | 2002-06-11 | 2002-12-25 | 中南大学湘雅医学院 | 抗纤维化吡啶酮药物及其生产工艺方法 |
CN101235030A (zh) * | 2007-01-30 | 2008-08-06 | 中南大学 | 1-取代-5-三氟甲基-2-(1h)吡啶酮化合物、制备方法及其用途 |
CN101237869A (zh) * | 2005-05-10 | 2008-08-06 | 英特芒尼公司 | 用于调节应激-活化蛋白激酶系统的吡啶酮衍生物 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4042699A (en) | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
US4052509A (en) | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
US3839346A (en) | 1972-12-18 | 1974-10-01 | Affiliated Med Res | N-substituted pyridone and general method for preparing pyridones |
GB8523126D0 (en) | 1985-09-19 | 1985-10-23 | Ici Plc | Aryl pyridones |
GB8621217D0 (en) | 1986-09-03 | 1986-10-08 | Ici Plc | Chemical compounds |
GB8825314D0 (en) | 1988-10-28 | 1988-11-30 | Ici Plc | Chemical compounds |
GB9006479D0 (en) | 1989-04-17 | 1990-05-23 | Ici Plc | Novel compounds |
US5310562A (en) | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
US5716632A (en) | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
US5518729A (en) | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
US5238906A (en) | 1990-11-27 | 1993-08-24 | Sumitomo Chemical Company, Limited | Pyridone derivatives and use |
DE4343528A1 (de) | 1993-12-16 | 1995-06-22 | Schering Ag | Zweifach heterocyclisch substituierte Benzole und Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel |
JP4164031B2 (ja) | 2002-02-14 | 2008-10-08 | ファルマシア コーポレーション | P38mapキナーゼのモジュレータとしての置換されたピリジノン |
US7166603B2 (en) | 2003-07-23 | 2007-01-23 | Bristol-Myers Squibb Co. | Dihydropyrimidone inhibitors of calcium channel function |
US7825133B2 (en) | 2003-11-14 | 2010-11-02 | Shanghai Genomics, Inc. | Derivatives of pyridone and the use of them |
DE102004027359A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyridin-2-onverbindungen und deren Verwendung |
ES2524922T3 (es) * | 2005-05-10 | 2014-12-15 | Intermune, Inc. | Derivados de piridona para modular el sistema de proteína cinasa activada por estrés |
WO2007053610A2 (en) | 2005-11-01 | 2007-05-10 | The Regents Of The University Of California | Methods of treating atrial fibrillation wtih pirfenidone |
EP2426134A3 (en) | 2005-11-23 | 2012-07-04 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
WO2008154207A1 (en) | 2007-06-08 | 2008-12-18 | The Burnham Institute For Medical Research | Methods and compounds for regulating apoptosis |
CN101371833A (zh) | 2007-08-23 | 2009-02-25 | 中南大学 | 1-芳基-2(1h)-吡啶酮类化合物在制备治疗皮肤瘙痒药物中的应用 |
US8304413B2 (en) * | 2008-06-03 | 2012-11-06 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
EP2389227A4 (en) | 2009-01-26 | 2012-08-08 | Intermune Inc | METHODS OF TREATING ACUTE MYOCARDIAL INFARCTION AND RELATED DISORDERS |
WO2010135470A1 (en) | 2009-05-19 | 2010-11-25 | Intermune, Inc. | Pifenidone derivatives for treating bronchial asthma |
-
2010
- 2010-05-24 WO PCT/CN2010/073105 patent/WO2010135972A1/zh active Application Filing
- 2010-05-24 AU AU2010252447A patent/AU2010252447B2/en not_active Ceased
- 2010-05-24 CN CN2010800025583A patent/CN102149682B/zh active Active
- 2010-05-24 EP EP10780053.4A patent/EP2436670B1/en not_active Not-in-force
- 2010-05-24 US US13/322,152 patent/US8426407B2/en not_active Expired - Fee Related
- 2010-05-24 JP JP2012512188A patent/JP5583758B2/ja not_active Expired - Fee Related
- 2010-05-24 KR KR1020117030518A patent/KR101522924B1/ko not_active IP Right Cessation
-
2012
- 2012-05-16 HK HK12104803.5A patent/HK1164297A1/zh not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1386737A (zh) * | 2002-06-11 | 2002-12-25 | 中南大学湘雅医学院 | 抗纤维化吡啶酮药物及其生产工艺方法 |
CN101237869A (zh) * | 2005-05-10 | 2008-08-06 | 英特芒尼公司 | 用于调节应激-活化蛋白激酶系统的吡啶酮衍生物 |
CN101235030A (zh) * | 2007-01-30 | 2008-08-06 | 中南大学 | 1-取代-5-三氟甲基-2-(1h)吡啶酮化合物、制备方法及其用途 |
Also Published As
Publication number | Publication date |
---|---|
JP2012527487A (ja) | 2012-11-08 |
CN102149682A (zh) | 2011-08-10 |
KR101522924B1 (ko) | 2015-05-26 |
WO2010135972A1 (zh) | 2010-12-02 |
AU2010252447B2 (en) | 2014-08-28 |
EP2436670B1 (en) | 2014-04-16 |
EP2436670A4 (en) | 2012-11-21 |
AU2010252447A1 (en) | 2011-12-15 |
JP5583758B2 (ja) | 2014-09-03 |
US8426407B2 (en) | 2013-04-23 |
HK1164297A1 (zh) | 2012-10-12 |
KR20120025541A (ko) | 2012-03-15 |
US20120142688A1 (en) | 2012-06-07 |
EP2436670A1 (en) | 2012-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102149682B (zh) | 1-(取代芳基)-5-三氟甲基-2-(1h)吡啶酮化合物及其盐的制备方法及其用途 | |
CN102149683B (zh) | 1-(取代苄基)-5-三氟甲基-2-(1h)吡啶酮化合物及其盐,其制备方法及其用途 | |
CN102060809B (zh) | 一种大黄酸衍生物及其制备和用途 | |
JP2018524298A (ja) | リンパ腫を処置するためのezh2阻害剤 | |
WO2010097332A1 (de) | Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids | |
WO2010046013A1 (de) | Azaindolderivate | |
CN102329325B (zh) | 吡咯并嘧啶酮类dpp-iv抑制剂 | |
TWI403320B (zh) | 用於抑制bcl蛋白和結合夥伴間之交互作用的化合物及方法 | |
CN101817833A (zh) | Dpp-iv抑制剂 | |
KR20160006207A (ko) | 사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도 | |
DE602004010845T2 (de) | Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen | |
AU2015341177A1 (en) | Six-membered ring benzo derivatives as DPP-4 inhibitor and use thereof | |
CN101407499A (zh) | 具有抗球虫活性的三嗪类化合物及其制备方法 | |
JP2023111961A (ja) | 悪性腫瘍を特定するためのキット及びその使用 | |
CN103664974A (zh) | 芳基[a]吲哚[2,3-g]并喹嗪类化合物、其制备方法、药物组合物及其应用 | |
CN103992236A (zh) | 一种新型靶向性抗肿瘤药物及其制备方法与应用 | |
WO2011095807A1 (en) | Combinations of mek and hh inhibitors | |
CN111718325A (zh) | 一种2,4,5-取代嘧啶类化合物及其制备方法和应用 | |
CN115093404B (zh) | 苯并五元杂环磺酰胺类化合物、其制备方法、药物组合物及应用 | |
CN114315705A (zh) | 一类urat1抑制剂及其制备方法与用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |